research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
Search
for
Sort by
Research
26 / 26 results 
research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
research Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide
Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
research Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research Efficacy and Safety of Proxalutamide in Severe or Critically Ill COVID-19 Patients: Study Protocol for an Exploratory Trial
The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
research Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users
Anabolic steroid users may face higher risk of severe COVID-19.
research Drug Repositioning Approach to Target Viral and Host Cells for COVID-19 Treatment: A Review of In Vivo Experiments and Clinical Studies
Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
research Extraordinary Claims Without Extraordinary Evidence: Controversy on Anti-Androgen Therapy for COVID-19
The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.
research Letter to the Editor on COVID-19 Infection in Men on Testosterone Replacement Therapy
The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.
research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research COVID-19, Androgens, and Androgenic Alopecia
COVID-19 may worsen with androgens; anti-androgen drugs could help.
research Reply to Comment on: The Gabrin Sign
Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.
research An Update on Antiviral Treatment of COVID-19
As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial
Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
research Alopecia in Patients with COVID-19: A Systematic Review and Meta-Analysis
Some COVID-19 patients lose hair, with the most common type linked to male hormones and possibly increasing the risk of severe illness.
research Are Sex Hormones Promising Candidates to Explain Sex Disparities in the COVID-19 Pandemic?
Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
research Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
research The Immune Response to COVID-19: Does Sex Matter?
Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.
research Roles of Steroid Receptors in the Lung and COVID-19
Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
research Sex Hormones in SARS-CoV-2 Susceptibility: Key Players or Confounders?
Sex hormones' effects on COVID-19 are unclear and more research is needed to understand their potential as treatment.
research Protective Trend of Anti-Androgen Therapy During the COVID-19 Pandemic: A Meta-Analysis
Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
research Association of Androgenetic Alopecia with a More Severe Form of COVID-19 Infection
Men with androgenetic alopecia and hypertension may experience more severe COVID-19.
research SARS-CoV-2 Vaccination in Androgen Sensitive Phenotypes – A Study on Associated Factors for SARS-CoV-2 Vaccination and Its Adverse Effects Among Androgenetic Alopecia and Benign Prostate Hyperplasia Patients
Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
research Editor's Picks January 2021
PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.